The Uttar Pradesh Food Safety and Drug Administration (FSDA) has forwarded six regulatory proposals to the Union Ministry calling for sweeping reforms in the drug distribution chain to rein in the illegal trade of codeine-based cough syrups, which are reportedly being diverted and misused as intoxicants across the state. The proposals were communicated through a formal reminder sent by FSDA Secretary and Commissioner Dr Roshan Jacob, who urged an early decision and the issuance of necessary guidelines.

What the Investigation Found

A departmental investigation revealed that large quantities of codeine-containing cough syrups were being billed by distributors, yet a significant portion never reached authorised retail outlets. An inter-state probe further uncovered parallel distribution networks, with supply routes traced to Ranchi, Himachal Pradesh, and other states outside Uttar Pradesh.

In multiple instances, physical stock did not match billed quantities, and records confirming retail-level distribution were either absent or unreliable. Based on these serious irregularities, FIRs have been lodged against 161 firms across 36 districts under the Bharatiya Nyaya Sanhita (BNS) and the Narcotic Drugs and Psychotropic Substances (NDPS) Act. Licence cancellation proceedings against the implicated firms have also been initiated.

The Six Key Proposals

The FSDA has urged major pharmaceutical companies — including Abbott, 3B, Wings, and others — to supply codeine-based products exclusively through authorised Carrying and Forwarding Agents (CFAs) and licensed stockists within Uttar Pradesh. Parallel distribution channels involving external intermediaries solely for codeine products must be discontinued, the department said.

A second proposal calls for scientifically assessing actual medical demand in each state rather than merely allocating production quotas to manufacturers. The required quantity for Uttar Pradesh should be determined on the basis of historical consumption data, patient needs, and genuine market demand.

Third, the FSDA has proposed that manufacturers must notify the concerned state drug controller before dispatching any consignment, furnishing advance details on quantity, batch numbers, supplier identity, and destination. A fourth measure advocates restricting wholesale-to-wholesale transactions to ensure medicines flow only through authorised channels down to the retail level.

Fifth, the regulator has recommended a QR code and barcode-based Track and Trace system for codeine syrups — modelled on the mechanism already in use for tuberculosis medicines — enabling batch-level reporting, real-time monitoring, and risk-based alerts from manufacturer to point of final sale. Sixth, the FSDA has proposed creating a distinct Schedule H3 category for medicines with a higher misuse potential, along with state-specific stock limits calibrated to actual consumption patterns.

Why This Matters for Patients and Pharmacies

The FSDA has been careful to clarify that codeine-based cough syrups are neither counterfeit products nor entirely prohibited substances — they are legally approved pharmaceuticals prescribed by doctors for severe cough and specified medical conditions. The department has stressed that the proposed reforms must not obstruct access for patients with a genuine medical need, and that authorised medical stores should continue dispensing them without disruption.

What Happens Next

The proposals now await a response from the Union Ministry of Health. If accepted, the reforms would represent one of the most comprehensive overhauls of controlled-medicine distribution oversight in recent years. Industry bodies and state drug controllers in other states affected by similar diversion patterns are likely to watch the Centre's response closely, as a positive ruling could set a national precedent for tracking high-risk pharmaceuticals.